PerkinElmer boosts reagents assets with purchase of GE Healthcare’s Catalog Radiochemical products

Seeking to enhance its reagent solution offerings, PerkinElmer Inc. announced today that it has purchased the assets of GE Healthcare’s 3H and 14C Catalog Radiochemicals, Scintillation Proximity Assay (SPA) reagents and Cytostar-T plate product lines. The company said the acquisition adds offerings for detection and screening of potential new drugs and expands its radiolabeling and bead-based assay technologies, enabling it to provide the world’s largest selection of high-quality radiolabeled compounds to the global scientific community.

Register for free to listen to this article
Listen with Speechify
0:00
5:00
WALTHAM, Mass.—Seeking to enhance its reagent solutionofferings, PerkinElmer Inc. announced today that it has purchased the assets ofGE Healthcare's 3H and 14C Catalog Radiochemicals, Scintillation ProximityAssay (SPA) reagents and Cytostar-T plate product lines.
 
 
The company said the acquisition adds offerings fordetection and screening of potential new drugs and expands its radiolabelingand bead-based assay technologies, enabling it to provide the world's largestselection of high-quality radiolabeled compounds to the global scientificcommunity. 
 
 
In addition, PerkinElmer said it also plans to continue toexpand its NEN radiochemical portfolio, as well as offer its extensive lines ofreaders, nuclear counters and other high-performance instrumentation thatprovide customers with complete application solutions in radiometric detection.
 
Financial terms of the deal were not disclosed.
 
 
GE Healthcare's Catalog Radiochemical products are used fora variety of research applications, including screening of potential drugcandidates through binding assays. The SPA bead-based light-emitting assay and Cytostar-T platetechnologies are offerings that enable the automation of high-throughputScreening (HTS) processes, to help drug discovery researchers quickly andaccurately determine if potential new drug compounds are effective againsttheir intended disease targets.
 
"PerkinElmer is delighted to announce this enhancement toour reagents assets," said Richard M. Eglen, PhD, president of Bio-discovery atPerkinElmer, in a statement. "We expect that the incorporation of thesetechnologies will strengthen our industry-leading GPCR and kinase researchproduct lines, and complement our HTS and research reagent solutions. Thisasset purchase reinforces PerkinElmer's continued position as the leadingcompany in HTS radiochemicals and related instruments, as we remain committedto supporting critical radiochemicals-based research."
 
Further details on the deal will be reported in ddn'sOctober 2009 issue.


Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN July 2024 Magazine Issue

Latest Issue  

• Volume 20 • Issue 4 • July 2024

July 2024

July 2024 Issue